Recent Updates
Recently added Catalysts
AMRN Positive Sentiment

Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026

Key Takeaway: Amarin Corporation announced it will report its first quarter 2026 financial results on April 29, 2026. A press release will precede a conference call with senior management at 8:00 a.m. ET. The call will be accessible via telephone and online, with a replay available for later access.
Price reaction · baseline $14.55 (2026-04-14 close) · hit after-hours · clean, no other AMRN news in the window
day 0 close · peak
+4.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Amarin is committed to advancing cardiovascular therapeutics.
  • The company has a proven track record of efficacy and safety.
  • Amarin's global reach covers nearly 100 markets.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+40%
120-day peak, hindsight
Typical move
5.6%
average across 2 past catalysts
Cash runway
~78 mo
Minimal dilution risk
Lead asset
AMR101 - /day
Phase 3 · Hypertriglyceridemia

Full Press Release Details

DUBLIN and BRIDGEWATER, N.J., April 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report first quarter 2026 financial results and conduct a conference call on Wednesday, April 29, 2026. The Company will issue a press release detailing its first quarter 2026 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET.
Information on how to participate is as follows.
Access to the live call:Via telephone: Dial in within the United States: 888-506-0062International dial in: 973-528-0011Access Code: 543818
Via online: A webcast of the call will be available on the Investor Relations section of the Company's website atwww.amarincorp.com.Access to the replay:Via telephone: Dial in within the United States: 877-481-4010International dial in: 919-882-2331Replay Code: 53836
Via online: A replay of the webcast will be accessible through the Investor Relations section of the Company's website atwww.amarincorp.com, beginning shortly after the end of the live call and available until 10/29/26.
About AmarinAmarin is a global pharmaceutical company committed to reducing the cardiovascular disease (CVD) burden for patients and communities and to advancing the science of cardiovascular care around the world. We own and support a global branded product approved by multiple regulatory authorities based on a track record of proven efficacy and safety and backed by robust clinical trial evidence. Our commercialization model includes a direct sales approach in the U.S. and an indirect distribution strategy internationally, through a syndicate of reputable and well-established partners with significant geographic expertise, covering close to 100 markets worldwide. Our success is driven by a dedicated, talented, and highly skilled team of experts passionate about the fight against the world’s leading cause of death, CVD.
Availability of Other Information About AmarinAmarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (http://www.amarincorp.com/investor-relations), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Amarin Contact InformationMedia Inquiries:Tegan BerryAmarin Corporation plcPR@amarincorp.com

Investor Inquiries:Devin Sullivan & Conor RodriguezThe Equity Group on Behalf of Amarindsullivan@theequitygroup.comorcrodriguez@theequitygroup.comInvestor.relations@amarincorp.com

Frequently Asked Questions

When will Amarin report its Q1 2026 financial results?

Amarin will report its Q1 2026 financial results on April 29, 2026.

What time is the Amarin conference call?

The conference call will take place at 8:00 a.m. ET.

How can I access the Amarin conference call?

You can access the call via telephone or online through Amarin's website.

Is there a replay available for the conference call?

Yes, a replay will be available shortly after the live call.

Last updated: Apr 15, 2026